[go: up one dir, main page]

MX2009003229A - Composiciones y metodos para diagnosticar y tratar cancer. - Google Patents

Composiciones y metodos para diagnosticar y tratar cancer.

Info

Publication number
MX2009003229A
MX2009003229A MX2009003229A MX2009003229A MX2009003229A MX 2009003229 A MX2009003229 A MX 2009003229A MX 2009003229 A MX2009003229 A MX 2009003229A MX 2009003229 A MX2009003229 A MX 2009003229A MX 2009003229 A MX2009003229 A MX 2009003229A
Authority
MX
Mexico
Prior art keywords
treating cancer
diagnosing
compositions
methods
dll4
Prior art date
Application number
MX2009003229A
Other languages
English (en)
Inventor
Austin Gurney
Timothy Hoey
Sanjeev Satyal
Fumiko Axelrod
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MX2009003229A publication Critical patent/MX2009003229A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describe un anticuerpo aislado que se une de manera específica a un dominio extracelular de DLL4 humano y afecta el crecimiento de un tumor que comprende células madre de cáncer. También se describe un método para tratar cáncer que comprende administrar una cantidad terapéuticamente efectiva de un anticuerpo anti-DLL4.
MX2009003229A 2006-09-29 2007-09-28 Composiciones y metodos para diagnosticar y tratar cancer. MX2009003229A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84790406P 2006-09-29 2006-09-29
US88626007P 2007-01-23 2007-01-23
US94254207P 2007-06-07 2007-06-07
PCT/US2007/020889 WO2008042236A2 (en) 2006-09-29 2007-09-28 Compositions and methods for diagnosing and treating cancer

Publications (1)

Publication Number Publication Date
MX2009003229A true MX2009003229A (es) 2009-06-18

Family

ID=39268983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003229A MX2009003229A (es) 2006-09-29 2007-09-28 Composiciones y metodos para diagnosticar y tratar cancer.

Country Status (27)

Country Link
US (5) US7750124B2 (es)
EP (3) EP2066694B1 (es)
JP (3) JP5535633B2 (es)
KR (1) KR101477824B1 (es)
AU (1) AU2007305443B2 (es)
BR (1) BRPI0717431A2 (es)
CA (1) CA2664738C (es)
CO (1) CO6180466A2 (es)
CR (1) CR10667A (es)
CY (1) CY1117154T1 (es)
DK (1) DK2066694T3 (es)
EA (1) EA018260B1 (es)
ES (1) ES2557953T3 (es)
HR (1) HRP20160082T1 (es)
HU (1) HUE028379T2 (es)
IL (1) IL197721A (es)
MA (1) MA30808B1 (es)
ME (1) ME02371B (es)
MX (1) MX2009003229A (es)
NO (1) NO20091635L (es)
NZ (1) NZ576404A (es)
PL (1) PL2066694T3 (es)
PT (1) PT2066694E (es)
RS (1) RS54452B1 (es)
SI (1) SI2066694T1 (es)
WO (1) WO2008042236A2 (es)
ZA (1) ZA200901615B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
EP2032166B1 (en) 2006-06-13 2013-04-10 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
MX2009003229A (es) * 2006-09-29 2009-06-18 Oncomed Pharm Inc Composiciones y metodos para diagnosticar y tratar cancer.
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008091641A2 (en) * 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2010517944A (ja) * 2007-01-26 2010-05-27 バイオインヴェント インターナショナル アーベー Ｄｌｌ４シグナリング阻害薬およびその使用
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
ES2553169T5 (es) 2007-07-02 2023-11-30 Oncomed Pharm Inc Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
US8119366B2 (en) * 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
PL3085773T3 (pl) * 2008-05-30 2021-01-11 Xbiotech, Inc Zastosowanie przeciwciał il-1 alfa
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
RU2010153578A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8226943B2 (en) 2008-07-08 2012-07-24 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
WO2010019702A2 (en) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Ddr1-binding agents and methods of use thereof
KR20110057244A (ko) * 2008-09-19 2011-05-31 메디뮨 엘엘씨 Ｄｌｌ4에 대한 항체 및 이의 용도
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
RU2546254C9 (ru) 2008-11-07 2015-07-10 Гэлэкси Биотех, Ллс. Моноклональные антитела к рецептору 2 фактора роста фибробластов
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
NZ598524A (en) * 2009-08-29 2014-06-27 Abbvie Inc Therapeutic dll4 binding proteins
AU2010289527C1 (en) 2009-09-01 2014-10-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011063237A2 (en) 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
US20110165162A1 (en) * 2009-12-01 2011-07-07 Oncomed Pharmaceuticals, Inc. Methods for Treating Cancers Comprising K-ras Mutations
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
JP2013540995A (ja) * 2010-08-18 2013-11-07 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 疾患に対する循環バイオマーカー
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012068098A1 (en) * 2010-11-15 2012-05-24 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2691776A4 (en) 2011-03-27 2015-04-15 Oncostem Diagnostics Mauritius Pvt Ltd MARKERS FOR IDENTIFICATION OF TUMOR CELLS AND METHOD AND KIT THEREFOR
WO2012174394A1 (en) * 2011-06-17 2012-12-20 Harris Adrian L Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2013039954A1 (en) * 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
PT3485903T (pt) * 2011-09-23 2023-02-17 Mereo Biopharma 5 Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
US10174107B2 (en) 2012-05-31 2019-01-08 Sorrento Therapeutics, Inc. Antigen binding proteins that bind delta-like 4 (DLL-4)
EP3202419A1 (en) 2012-06-06 2017-08-09 OncoMed Pharmaceuticals, Inc. Pvrig binding agents that modulate the hippo pathway and uses thereof
AU2013289990B2 (en) 2012-07-13 2018-06-14 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US20150368329A1 (en) * 2012-10-15 2015-12-24 Oncomed Pharmaceuticals, Inc. Methods of Treating Ocular Diseases
EP2914961A4 (en) * 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
TW202014439A (zh) 2012-11-01 2020-04-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
BR112015013127A2 (pt) 2012-12-04 2017-09-26 Oncomed Pharm Inc imunoterapia com agentes de ligação
JP6449537B2 (ja) * 2012-12-27 2019-01-09 日本メジフィジックス株式会社 抗腫瘍剤、及び、抗腫瘍用キット
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
GB201312727D0 (en) * 2013-07-16 2013-08-28 Isis Innovation Modulators
PE20210949A1 (es) 2013-08-01 2021-05-24 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados
CN105829547A (zh) 2013-12-02 2016-08-03 昂科梅德制药有限公司 与Wnt途径抑制剂有关的预测性生物标记物的鉴别
JPWO2015108203A1 (ja) * 2014-01-15 2017-03-23 株式会社オーダーメードメディカルリサーチ 抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物
LT3172227T (lt) * 2014-07-21 2020-02-10 Delinia, Inc. Molekulės, kurios selektyviai aktyvina reguliacines t ląsteles, skirtos autoimuninių ligų gydymui
EP3193935A4 (en) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
PT3212233T (pt) 2014-10-31 2020-07-16 Oncomed Pharm Inc Terapia combinada para o tratamento de doenças
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
MX2018006181A (es) 2015-11-23 2018-09-24 Five Prime Therapeutics Inc Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP7035026B2 (ja) 2016-05-19 2022-03-14 サンタ アナ テック エルエルシー 加熱された切除ゾーンを生成し組織に適用するためのダブルバルーン構造を有するカテーテル
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling
EP3474854A4 (en) 2016-06-27 2020-02-19 The Regents of The University of California DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER
US11401332B2 (en) 2016-08-23 2022-08-02 The Regents Of The University Of California Proteolytically cleavable chimeric polypeptides and methods of use thereof
UA127450C2 (uk) * 2016-09-21 2023-08-30 Аптево Рісьорч Енд Дівелопмент Елелсі Рекомбінантний поліпептид, що зв'язується з cd123
CA3041334A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
JP7126269B2 (ja) 2016-11-30 2022-08-26 メレオ バイオファーマ ５ インコーポレイテッド Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法
IL270454B1 (en) 2017-05-16 2025-06-01 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
AU2019338398A1 (en) 2018-09-11 2021-05-20 Aqua Heart, Inc. Heated vapor ablation systems and methods for treating cardiac conditions
AU2019380595A1 (en) 2018-11-15 2021-06-03 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with VEGF/DLL4 binding agent
EP4021326A4 (en) 2019-08-28 2023-09-13 Santa Anna Tech LLC SYSTEMS AND PROCEDURES FOR PROSTATE TISSUE ABLATION
US20210212745A1 (en) 2020-01-15 2021-07-15 Aqua Medical, Inc. Vapor Ablation System with Simplified Control Over Vapor Delivery
EP4225180A4 (en) 2020-10-08 2024-10-30 Santa Anna Tech LLC VISUALIZATION-CAPABLE ABLATION CATHETERS, SYSTEMS AND PROCEDURES
WO2023149977A1 (en) * 2022-02-04 2023-08-10 Mereo Biopharma 5, Inc. Methods for treating cancer

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2248608B1 (es) * 1973-10-17 1977-05-27 Labo Electronique Physique
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US20050112121A1 (en) 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1997001571A1 (en) 1995-06-28 1997-01-16 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
JPH09124697A (ja) 1995-11-01 1997-05-13 Toagosei Co Ltd ペプチド及びモノクローナル抗体
US6337387B1 (en) 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6121045A (en) 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
US20030180784A1 (en) 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
WO1998045434A1 (en) 1997-04-04 1998-10-15 Millennium Biotherapeutics, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE122005000026I1 (de) 1997-04-07 2005-08-04 Genentech Inc Anti-VEGF Antik¦rper.
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
EP0977853A1 (en) 1997-04-25 2000-02-09 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6664098B1 (en) 1997-05-14 2003-12-16 Asahi Kasei Kabushiki Kaisha Differentiation inhibitory agent
WO1998057621A1 (en) 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
EP1100899A2 (en) 1998-07-27 2001-05-23 Amgen Inc. Delta-related polypeptides
ES2223705T3 (es) 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
SK287332B6 (sk) 1999-06-08 2010-07-07 Regeneron Pharmaceuticals, Inc. Izolovaná molekula nukleovej kyseliny, fúzny polypeptid ňou kódovaný, vektor s jej obsahom, systém vektor-hostiteľ na reprodukciu fúzneho polypeptidu a spôsob jeho prípravy, antagonista dimérneho VEGF a použitie
EP1196570A2 (en) 1999-07-26 2002-04-17 Genentech, Inc. Human polypeptides and methods for the use thereof
EP1690873A3 (en) 1999-12-01 2006-08-23 Genentech, Inc. Composition and methods for the diagnosis of tumours
WO2001077169A2 (en) 2000-04-05 2001-10-18 Kirin Beer Kabushiki Kaisha Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
GB0014185D0 (en) * 2000-06-09 2000-08-02 Novartis Res Found Compound and method
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
JP2004536877A (ja) 2001-07-25 2004-12-09 ロランティス リミテッド 免疫療法に用いるノッチシグナル伝達モジュレーター
EP1414964B1 (en) 2001-08-01 2010-03-24 University Of Bristol Vegf isoform
EP1446424A2 (en) * 2001-11-14 2004-08-18 Lorantis Limited Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system
JP2005526701A (ja) 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
US20050137130A1 (en) 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
CA2469204A1 (en) * 2001-12-07 2003-06-19 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
GB0218879D0 (en) 2002-08-14 2002-09-25 Lorantis Ltd Medical treatment
JP2006515177A (ja) 2002-09-10 2006-05-25 ロランティス リミテッド Ｎｏｔｃｈリガンドタンパク質を含む医薬組成物及び医学的処置
EP1631317A2 (en) 2003-06-06 2006-03-08 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
AU2004263538B2 (en) 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
FR2859725B1 (fr) 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
WO2005123104A2 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
JP2008503481A (ja) 2004-06-18 2008-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 悪性胸膜滲出液の処置のためのｖｅｇｆインヒビターの投与および使用の方法
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
EP1786906A2 (en) 2004-09-09 2007-05-23 Exonhit Therapeutics SA Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
BRPI0517564A (pt) 2004-11-10 2008-10-14 Hubrecht Lab métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica
EP1812064A4 (en) 2004-11-19 2009-07-08 Cornell Res Foundation Inc USE OF VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 1+ CELLS IN THE TREATMENT AND MONITORING OF CANCER AND SCREENING IN CHEMOTHERAPY
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
EP1853298A2 (en) 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
EP1868650B1 (en) 2005-04-15 2018-10-03 MacroGenics, Inc. Covalent diabodies and uses thereof
KR20080026562A (ko) 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
JP2009504679A (ja) 2005-08-12 2009-02-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆアンタゴニストを用いて疾患を処置する方法
CA2621226A1 (en) 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
PL1962895T3 (pl) 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
EP1993541A2 (en) 2006-02-17 2008-11-26 Gilead Colorado, Inc. Antihypertensive therapy
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
EP2029159A2 (en) * 2006-06-06 2009-03-04 Genentech, Inc. Compositions and methods for modulating vascular development
JP2009539384A (ja) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 抗ｄｌｌ４抗体および抗ｄｌｌ４抗体使用の方法
EP2032166B1 (en) 2006-06-13 2013-04-10 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
ME00591A (en) 2006-08-07 2011-12-20 Use of dii4 antagonists in ishemic injury or vascular insufficiency
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
MX2009003229A (es) 2006-09-29 2009-06-18 Oncomed Pharm Inc Composiciones y metodos para diagnosticar y tratar cancer.
MX2009004027A (es) 2006-10-20 2009-09-28 Schering Corp Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.
WO2008070042A2 (en) 2006-12-04 2008-06-12 Medimmune, Inc. High potency recombinant antibodies, methods for producing them and use in cancer therapy
WO2008073509A2 (en) 2006-12-11 2008-06-19 Genentech, Inc. Compositions and methods for treating a neoplasm
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
HUE029445T2 (en) 2006-12-19 2017-02-28 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
EP2120996A2 (en) 2006-12-20 2009-11-25 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
JP2010517944A (ja) * 2007-01-26 2010-05-27 バイオインヴェント インターナショナル アーベー Ｄｌｌ４シグナリング阻害薬およびその使用
EP2671584A3 (en) 2007-05-04 2014-03-26 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009055343A2 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
US8592563B2 (en) 2007-10-25 2013-11-26 Philogene, Inc. Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF)
WO2009075565A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
CA2709847C (en) 2008-01-07 2018-07-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
CA2740341C (en) 2008-12-12 2019-05-07 Boehringer Ingelheim International Gmbh Anti-igf antibodies
AR076344A1 (es) 2009-04-20 2011-06-01 Genentech Inc Metodo de terapia complementaria contra el cancer
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
JP2012532608A (ja) 2009-07-08 2012-12-20 アムジェン インコーポレイテッド ＣＨ３ドメイン界面操作を通じた、安定でそして凝集しない抗体Ｆｃ分子の設計
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
CA2778084A1 (en) 2009-10-23 2011-04-28 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
US20110165162A1 (en) 2009-12-01 2011-07-07 Oncomed Pharmaceuticals, Inc. Methods for Treating Cancers Comprising K-ras Mutations
KR20120117931A (ko) 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
WO2012068098A1 (en) 2010-11-15 2012-05-24 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
PT3485903T (pt) 2011-09-23 2023-02-17 Mereo Biopharma 5 Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
AU2013289990B2 (en) 2012-07-13 2018-06-14 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4

Also Published As

Publication number Publication date
ME02371B (me) 2016-06-20
NZ576404A (en) 2012-02-24
US20140147443A9 (en) 2014-05-29
IL197721A (en) 2015-03-31
CY1117154T1 (el) 2017-04-05
HRP20160082T1 (hr) 2016-02-26
US7750124B2 (en) 2010-07-06
US20080187532A1 (en) 2008-08-07
EP2562188A2 (en) 2013-02-27
SI2066694T1 (sl) 2016-02-29
US20130266569A1 (en) 2013-10-10
KR20090078334A (ko) 2009-07-17
AU2007305443A1 (en) 2008-04-10
NO20091635L (no) 2009-06-26
EA018260B1 (ru) 2013-06-28
EP2066694B1 (en) 2015-11-04
BRPI0717431A2 (pt) 2013-11-12
PT2066694E (pt) 2016-01-27
CR10667A (es) 2009-05-25
JP5997194B2 (ja) 2016-09-28
ES2557953T3 (es) 2016-01-29
ZA200901615B (en) 2009-12-30
EP2066694A4 (en) 2010-05-05
WO2008042236A2 (en) 2008-04-10
JP2017002076A (ja) 2017-01-05
KR101477824B1 (ko) 2015-01-02
US20100316637A1 (en) 2010-12-16
MA30808B1 (fr) 2009-10-01
PL2066694T3 (pl) 2016-04-29
US20160367667A1 (en) 2016-12-22
EP2066694A2 (en) 2009-06-10
AU2007305443B2 (en) 2012-08-23
US20190060453A1 (en) 2019-02-28
JP2010504755A (ja) 2010-02-18
HUE028379T2 (en) 2016-12-28
EP3357932A1 (en) 2018-08-08
DK2066694T3 (en) 2016-02-08
IL197721A0 (en) 2011-08-01
CO6180466A2 (es) 2010-07-19
WO2008042236A3 (en) 2008-07-31
US9376497B2 (en) 2016-06-28
HK1133268A1 (en) 2010-03-19
EA200970335A1 (ru) 2009-10-30
JP5535633B2 (ja) 2014-07-02
JP2014158469A (ja) 2014-09-04
CA2664738A1 (en) 2008-04-10
CA2664738C (en) 2017-03-07
EP2562188A3 (en) 2013-03-06
US9228020B2 (en) 2016-01-05
RS54452B1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
MX2009003229A (es) Composiciones y metodos para diagnosticar y tratar cancer.
WO2007145840A3 (en) Compositions and methods for diagnosing and treating cancer
EA201170158A1 (ru) Агенты, связывающиеся с рецептором notch1, и способы их применения
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
EA201170136A1 (ru) Мультимасштабный метод конечных объемов для моделирования резервуара
EP2481756A3 (en) Compositions and methods for diagnosing and treating cancer
DOP2012000295A (es) Anticuerpos hacia gdf8 humano
UA94899C2 (ru) Фиксированное дозирование антител к her
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
AR070821A1 (es) Anticuerpo anti- tyrp1 (antitiroxina humana)
RU2015110632A (ru) Молекулы, связывающиеся с 4-1вв
EA200870141A1 (ru) Комбинационная терапия с использованием антител к egfr и her2
WO2011063237A3 (en) Jagged-binding agents and uses thereof
NZ601293A (en) Compositions and methods for the diagnosis and treatment of tumor
UA99633C2 (ru) Антитело, специфически связывающееся с человеческим белком ron
GEP20135826B (en) Novel antibodies used to treat cancer
NZ704269A (en) Rspo3 binding agents and uses thereof
NZ592369A (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
WO2009158432A3 (en) Ang-2 inhibition to treat multiple sclerosis
CA2740134C (en) Formulations targeting igfbp7 for diagnosis and therapy of cancer
EP2068929A4 (en) METHOD OF DETECTING AND TREATING SKIN DISORDERS
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
AU2006332806A8 (en) Na+, K+-ATPase expression in cervical dysplasia and cancer
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer

Legal Events

Date Code Title Description
FG Grant or registration